PDCD1 and cancer: More than 150 unique exosomal miRNAs are identified in cancer patients, and hsa-miR-320d, hsa-miR-320c, and hsa-miR-320b may be potential biomarkers to predict treatment efficacy of PD-1/PD-L1 immunotherapy in lung cancers [108].